試す 金 - 無料
Quality Concerns Hits APAC
BioSpectrum Asia
|BioSpectrum Asia August 2023
India is not alone in witnessing adverse events of various drugs. Several countries such as Japan, China, Malaysia, Indonesia and many more have experienced challenges such as contamination, efficacy, and safety issues (with serious adverse events), resulting in drug recalls in the past few years. As with any incident, an in-depth look will bring forth the root of the problem. Let's explore.
In February 2023, the Drug Regulatory Authority of Pakistan (DRAP) recalled seven products manufactured by Islamabad-based Davis Pharmaceutical Laboratories in Pakistan because of the discovery of ethylene glycol at unacceptable levels.
The likely cause for contamination for KOF Relief Syrup and six other products were due to the using of the same sources of glycerin and propylene glycol. Four of the products, including KOF Relief Syrup, were manufactured for export.
DRAP was expected to take action against the syrup manufacturer, potentially by cancelling its production license and by subsequent arrests.
In June 2023, Pakistan published changes to its drug pricing policy. The revisions cover the definition of the term essential drugs and biologicals, which officials have expanded to cover all strengths of a medicine.
In March 2023, Malaysia’s Drug Control Authority (DCA) also recalled pholcodine-containing cough and cold medicines, citing the risk of anaphylaxis in surgery.
Australia’s Therapeutic Goods Administration (TGA) published a safety alert in February 2023 about Abbott’s FreeStyle LibreLink Android app. The alert describes a fault that could prevent users from receiving information they need to manage their blood sugar levels. According to TGA, users may experience extended periods of signal loss and during this time they won’t receive high or low glucose alarms.
Abbott has taken steps and has released the latest version of the FreeStyle LibreLink app (version 2.8.4), and has recommended Android 13 OS users of the FreeStyle Libre 2 to update their app to this latest version. Abbott has also released the latest version of the FreeStyle Libre 3 app (version 3.4.2).
このストーリーは、BioSpectrum Asia の BioSpectrum Asia August 2023 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
BioSpectrum Asia からのその他のストーリー
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Cancer Diagnosis, Accelerated by AI
Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.
13 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026
The oncology landscape in Asia stands at a critical juncture.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Pharma M&A set to boom in 2026
After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.
3 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
Translate
Change font size
